Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Business earnings report

Walmart reports slowest sales growth

Analysis based on 13 articles · First reported Aug 20, 2026 · Last updated Aug 20, 2026

Sentiment
-20
Attention
4
Articles
13
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Walmart's disappointing comparable sales growth and cautious guidance signal softening consumer demand, which could pressure retail sector stocks and broader market sentiment. The stock's 6% drop reflects investor concerns about future earnings, potentially impacting consumer discretionary indices and related ETFs.

Retail E-commerce Pharmaceuticals

Walmart reported its slowest U.S. comparable sales growth in six years for the second quarter, with comparable sales rising 2.6% versus 4.1% in the prior quarter. Excluding the wellness category, which was impacted by federal United States — Medicare drug pricing regulations, comparable sales rose 3.4%, still below analyst expectations of 3.8%. The company's U.S. e-commerce sales grew 24%, slowing from 26% in the first quarter. Walmart's net income was $6.37 billion, or 80 cents per share, with adjusted EPS of 81 cents beating expectations of 74 cents. Total sales rose 5.9% to $187.94 billion, slightly above forecasts. However, Walmart issued cautious guidance for the third quarter and full year, with EPS and sales forecasts below analyst estimates. Shares fell 6% in premarket trading. The results are seen as a barometer of consumer spending, especially amid weak July retail sales data and growing consumer pessimism, partly due to price pressures from the conflict in Iran.

90 Walmart slashed profit forecast
80 Walmart rose
70 Walmart reported sales
60 Walmart reported slowest comparable sales growth
50 United States enacted pharmacy regulations Walmart
stock
Walmart is the central entity, reporting its slowest comparable sales growth in six years and issuing cautious guidance, leading to a 6% stock drop. Despite beating earnings estimates, the weak sales and outlook weigh on its valuation.
Importance 100.0 Sentiment -30.0
cnt
The United States is the primary market for Walmart, and its regulatory actions on United States — Medicare drug pricing negatively impacted Walmart's pharmacy sales. Weak retail sales data and consumer pessimism in the U.S. contribute to the challenging environment.
Importance 60.0 Sentiment -10.0
govactor
United States — Medicare regulations requiring capped prices on high-cost drugs reduced Walmart's pharmacy sales, contributing to the slower comparable sales growth. This regulatory impact is a key factor in the quarter's results.
Importance 40.0 Sentiment -5.0
cnt
The conflict in Iran is cited as a source of price pressures that may be impacting consumer behavior, contributing to the cautious outlook and weak retail sales. It adds to the economic uncertainty affecting Walmart's performance.
Importance 25.0 Sentiment -15.0
stock
FactSet provided the analyst consensus estimates that Walmart's results were compared against, highlighting the miss on comparable sales and guidance. It serves as a benchmark for market expectations.
Importance 20.0 Sentiment 0.0
Walmart related United States
Walmart related Iran
Walmart related FactSet
United States at war Iran The United States is currently at war with Iran, conducting sustained airstrikes and enforcing a naval blockade, while f
United States related FactSet
Iran related FactSet
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.